{"uid":"cap_BicwJJJ1iUmcAl5wuuaKw","slug":"clinicalintelpulse-fda-ema-drug-approval-outlook-b10b73c2","name":"ClinicalIntelPulse FDA/EMA Drug Approval Outlook","description":"FDA/EMA drug approval probability + PDUFA calendar for a disease area — which Phase 3 drugs are most likely to win approval in 12-24 months, with mechanism, trial results, approval-probability scores and historical phase-3 success rates. Worldwide. For biotech-investing and payer agents.","url":"https://clinicalintelpulse.theaslangroupllc.com/api/clinical/approval-outlook","method":"GET","headers":{},"bodySchema":{"type":"object","$schema":"https://json-schema.org/draft/2020-12/schema","required":["input"],"properties":{"input":{"type":"object","required":["type","method"],"properties":{"type":{"type":"string","const":"http"},"method":{"enum":["GET","HEAD","DELETE"],"type":"string"},"queryParams":{"type":"object","properties":{"lang":{"type":"string"},"agency":{"type":"string"},"horizon":{"type":"string"},"condition":{"type":"string"}}}},"additionalProperties":false},"output":{"type":"object","required":["type"],"properties":{"type":{"type":"string"},"errors":{"type":"object","description":"Documented error responses, keyed by HTTP status code","additionalProperties":{"type":"object","required":["description"],"properties":{"example":{"type":"object"},"description":{"type":"string"}}}},"example":{"type":"object"}}}}},"responseSchema":{"type":"json","example":{"query_summary":{"horizon":"18m","agencies":["FDA","EMA"],"condition":"Alzheimer Disease"},"market_context":"Alzheimer's is the highest-value CNS approval category. Any successful amyloid or tau therapy represents $5-15B peak sales potential.","pdufa_calendar":[{"drug":"Donanemab","sponsor":"Eli Lilly","indication":"Early symptomatic AD","pdufa_date":"2025-Q2","priority_review":true}],"approval_candidates":[{"drug":"Lecanemab (Leqembi)","nctId":"NCT03887455","sponsor":"Eisai / Biogen","key_risk":"ARIA (amyloid-related imaging abnormalities) safety profile limiting real-world use","mechanism":"Anti-amyloid monoclonal antibody (protofibrils)","ema_status":"CHMP assessment ongoing 2025","fda_status":"Full approval received 2023; expanded label applications pending","trial_result":"Positive — 27% slowing of clinical decline vs placebo (p<0.001)","approval_probability":85}],"approval_rate_context":{"rare_disease_premium":"Breakthrough therapy designation adds ~15% probability uplift","us_approval_rate_phase3_pct":58,"disease_area_historical_phase3_success_pct":55}}},"example":null,"exampleRequest":null,"tags":["x402"],"displayCostAmount":"0.25","displayCostAsset":"USDC","priceDynamic":false,"priceHint":null,"priceStatus":"priced","priceSource":"probe","requiresHandshake":false,"reviewCount":0,"rating":{"score":"0.00","successRate":"0.00","reviews":0,"stars":null,"state":"unrated"},"availabilityStatus":"unknown","priceObserved":null,"sessionDeposit":null,"pricing":{"kind":"static","summary":"$0.25/call","primary":{"kind":"static","protocol":"x402","network":"base","amountUsd":"0.25","per":"call","confidence":"exact"},"accepted":[{"kind":"static","protocol":"x402","network":"base","amountUsd":"0.25","per":"call","confidence":"exact"}]},"paymentMethods":[{"uid":"pm_e3nbrmX71toLP1R4rEbl-","protocol":"x402","methodType":"crypto","chain":"base","mode":"charge","costAmount":"0.25","costPer":"request","priority":0,"asset":"0x833589fCD6eDb6E08f4c7C32D4f71b54bdA02913","unit":"request","depositMicros":null,"planRef":null}],"brandName":null,"brandSlug":null,"brandBaseUrl":null,"brandDocsUrl":null,"whatItDoes":"Returns FDA/EMA approval probability scores and PDUFA calendar for Phase 3 drugs in a given disease area, including mechanism of action, trial results, and historical phase-3 success rates.","exampleAgentPrompt":"What are the Phase 3 drugs most likely to win FDA or EMA approval in the next 12-24 months for non-alcoholic steatohepatitis (NASH) — I want approval probability scores, PDUFA dates, mechanism of action, and historical phase-3 success rates for the disease area.","exampleUseCases":[{"title":"Biotech portfolio risk assessment","prompt":"Can you pull the Phase 3 oncology drugs with the highest approval probability scores and show me their expected PDUFA dates? I'm trying to figure out which assets in our portfolio have the strongest near-term regulatory tailwinds and which ones carry more approval risk."},{"title":"Competitive intelligence for payer launch","prompt":"I need to understand what's coming down the pipeline for type 2 diabetes treatments in Phase 3. Give me the approval odds for each drug, their mechanisms of action, and the historical success rates so we can plan our payer strategy before these competitors hit the market."},{"title":"Rare disease investment due diligence","prompt":"Show me all the Phase 3 rare disease therapies and rank them by approval probability — I want to see the trial results, PDUFA timelines, and how the historical success rates in rare indications compare to other areas so I can decide which companies to invest in."}],"resultDescription":"A ranked list of Phase 3 drugs in the queried disease area, each with an approval probability score, expected PDUFA date, mechanism of action, summary of pivotal trial results, and the historical phase-3 success rate for that indication — sourced globally covering both FDA and EMA pipelines.","failureModes":["Unknown or misspelled disease area returns empty results or a 404","Disease area with no active Phase 3 trials returns an empty pipeline list","Overly broad therapeutic areas (e.g. 'cancer') may return truncated or paginated results","Stale PDUFA calendar data if FDA/EMA has not yet published dates for recent filings","Rate limiting or payment failure returns 402 Payment Required"],"whenToPreferThis":"Use this endpoint when you need forward-looking regulatory approval probability for late-stage (Phase 3) drugs in a specific disease area, particularly for biotech investment due diligence, payer launch planning, or competitive intelligence. Prefer this over a general trial landscape endpoint when the primary question is 'which drugs are most likely to be approved and when?' rather than 'what trials exist?'","instructions":null,"reviewSummary":null,"reviewSummaryHighlights":null,"reviewSummaryConcerns":null,"reviewSummaryGeneratedAt":null,"activationCount":0,"lastUsedAt":null,"lastSuccessfullyRanAt":null,"lastHealthCheckAt":"2026-09-14T00:40:53.499Z","isFirstParty":false}